ArticleFrontiers in oncology2025

Real-world multicenter study of rezvilutamide plus androgen deprivation therapy in Chinese patients with high-volume metastatic hormone-sensitive prostate cancer.

Shuang Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.